Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004123 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00004123: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00004123 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004123, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus doxorubicin in treating patients who have resectable primary or recurrent peritoneal soft tissue sarcoma.
Interventions
- RADIATION Radiation Therapy (RT)
- RADIATION Intraoperative radiation therapy (IORT)
- PROCEDURE Conventional surgery
- DRUG Doxorubicin hydrochloride (DOX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1997-07 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004123
The ClinicalTrials.gov registry entry for NCT00004123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy (RT) is the first listed.
NCT00004123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004123 about?
NCT00004123 is a clinical study titled "Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effec...
What is the current status of trial NCT00004123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1997-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00004123?
The interventions under investigation include: Radiation Therapy (RT) (RADIATION), Intraoperative radiation therapy (IORT) (RADIATION), Conventional surgery (PROCEDURE), Doxorubicin hydrochloride (DOX) (DRUG).
Who is sponsoring clinical trial NCT00004123?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.